Bay Capital Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.67M Sell
1,446
-20
-1% -$23.6K 0.89% 22
2026
Q2
$1.76M Sell
1,466
-1
-0.1% -$1.02K 0.94% 21
2026
Q1
$1.35M Sell
1,467
-14
-0.9% -$14.2K 0.83% 22
2025
Q4
$1.59M Buy
1,481
+2
+0.1% +$1.91K 0.97% 22
2025
Q3
$1.13M Sell
1,479
-3
-0.2% -$2.23K 0.73% 25
2025
Q2
$1.16M Sell
1,482
-49
-3% -$38.1K 0.88% 23
2025
Q1
$1.26M Buy
1,531
+4
+0.3% +$3.33K 1.05% 20
2024
Q4
$1.18M Hold
1,527
– – 0.95% 23

Other funds holding LLY

Bay Capital Advisors's LLY Position: Q3 2026 in Review

Bay Capital Advisors reduced its Eli Lilly (LLY) stake by 1.4% in Q3 2026, selling an estimated $23.6K and leaving 1,446 shares worth $1.67M. The position accounts for 0.89% of the portfolio, ranked #22.

Bay Capital Advisors first reported a position in LLY in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.76M in Q2 2026. 4,624 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Bay Capital Advisors held 1,446 shares of Eli Lilly worth $1.67M as of Q3 2026.
  • Bay Capital Advisors sold 20 Eli Lilly shares in Q3 2026, an estimated $23.6K.
  • Eli Lilly made up 0.89% of Bay Capital Advisors's portfolio in Q3 2026, its #22 holding.
  • Bay Capital Advisors first reported a position in Eli Lilly in Q4 2024 and has held it in 8 quarters since.
  • Bay Capital Advisors's Eli Lilly position peaked at $1.76M in Q2 2026.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Bay Capital Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.